Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients by Bhagwagar, Zubin et al.
Low GABA concentrations in occipital cortex
and anterior cingulate cortex in medication-free,
recovered depressed patients
Zubin Bhagwagar1, Marzena Wylezinska2, Peter Jezzard2, John Evans2,3, Erie Boorman3,
Paul M. Matthews2 and Philip J. Cowen3
1 Department of Psychiatry, Yale University, New Haven, CT, USA
2 Centre for Functional Magnetic Resonance Imaging of the Brain, John Radcliﬀe Hospital, Oxford, UK
3 Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
Abstract
Studies using proton magnetic resonance spectroscopy (1H-MRS) indicate that unmedicated, acutely de-
pressed patients have decreased levels of c-aminobutyric acid (GABA) in the occipital cortex. The aim of
this study was to use 1H-MRS to determine if changes in occipital and frontal cortical GABA levels were
present in patients with a history of depression who had recovered and were no longer taking medication.
We used 1H-MRS to measure levels of GABA in both occipital cortex and anterior cingulate cortex/
prefrontal cortex in medication-free, fully recovered subjects with a history of recurrent unipolar de-
pression. Levels of GABA in both occipital and anterior cingulate cortex were signiﬁcantly lower in re-
covered depressed subjects than healthy controls. Our data provide preliminary evidence that a history of
recurrent depression is associated with decreased GABA levels in anterior cingulate cortex and occipital
cortex. These changes could represent part of the neurobiological vulnerability to recurrent depressive
episodes.
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Introduction
Investigations using proton magnetic resonance spec-
troscopy (1H-MRS) have shown decreases in c-
aminobutyric acid (GABA) concentration in the
occipital cortex in unmedicated depressed patients
(Sanacora et al., 1999, 2004). Treatment with selective
serotonin re-uptake inhibitors and electroconvulsive
therapy, but not cognitive behavioural therapy,
increases cortical GABA levels in depressed subjects
(Sanacora et al., 2002, 2003, 2006). It is therefore im-
portant to establish whether low cortical GABA levels
in depression may be a trait marker of depression,
i.e. still detectable following clinical recovery and
withdrawal of antidepressant treatment.
For technical reasons MRS studies of acutely de-
pressed patients have usually measured GABA con-
centration in the occipital cortex; however, it is also
necessary to determine whether similar GABAergic
abnormalities are present in the frontal areas more
usually associated with the pathophysiology of de-
pression (Drevets, 1998). Abnormal activity of the an-
terior cingulate cortex (ACC) has been implicated in
functional imaging studies of depression (Drevets,
1998) and there is also evidence that this brain region
is aﬀected by neuropathological processes that could
be associated with lowered GABA availability
(Harrison, 2002).
The present study was a pilot investigation de-
signed to assess the feasibility of measuring GABA
levels in the occipital cortex and ACC in the same
scanning session. Our hypothesis was that GABA
concentrations would be decreased in both brain re-
gions in recovered depressed subjects in comparison
to healthy controls.
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Methods
Subjects
The 23 subjects studied were a subgroup of a larger
MRS investigation of the occipital cortex in patients
with recurrent mood disorder (Bhagwagar et al., 2007)
in whom it proved possible to measure GABA con-
centrations in both the occipital cortex and ACC in
the same scanning session. Participants included 11
healthy controls (7 males, 4 females) aged 34.3¡4.1 yr
with no psychiatric history and 12 patients (4 males,
8 females) aged 40.6¡4.2 yr who had experienced at
least two episodes of unipolar major depression in the
past (‘recovered depressed’). All patients had been
medication-free and euthymic for a minimum of 6
months. Subjects were screened using the Structured
Clinical Interview for DSM-IV Disorders (SCID; First
et al., 1997). Subjects were rated to be recovered from
depression on four criteria : self-reported recovery,
the absence of clinically relevant symptoms during a
clinical interview with an experienced psychiatrist,
absence of criterion for a major depressive episode
judged by the SCID, and a score of<7 on the 17-item
Hamilton Rating Scale for Depression. All female
subjects were scanned in the ﬁrst half of the menstrual
cycle. The study was approved by the Oxfordshire
Psychiatric Research Ethics Committee. All subjects
gave written informed consent for participation in the
study.
MRS methodology
All subjects were scanned between 13:00 and 17:00
hours, using a 3 T Varian INOVA system (Varian Inc.,
Palo Alto, CA, USA), with dedicated head gradient
coil (Magnex Scientiﬁc, Oxford, UK), and head-only
transmit/receive quadrature birdcage RF coil. MRS
data were acquired from-two 30r30r20 mm voxels ;
one in the occipital-parietal region of the brain, and the
other in the anterior cingulate region. The voxels were
positioned on a T1-weighted axial image, located
slightly above the corpus callosum (Figure 1). The oc-
cipital voxel was positioned to include parts of the
posterior cingulate gyrus, parietal lobe and occipital
lobe. This brain region oﬀers clear landmarks for
placement of the spectroscopic voxel, and is removed
from major sources of static magnetic-ﬁeld in-
homogeneities greatly facilitating measurement of
cortical GABA levels. The ACC voxel was centred on
the anterior part of the cingulate sulcus, such that the
voxel included parts of the anterior cingulate and the
pre-frontal cortex.
1H point-resolved spectroscopy sequence (PRESS;
Bottomley, 1984) spectra with water suppression were
acquired with the following parameters ; repetition
time (TR)=3 s, echo time (TE)=68 ms, 32 averages,
1024 complex acquisition points. The total acquisition
time for each PRESS spectrum was y1.5 min. GABA
measurements were made using a MEGA-PRESS
editing sequence (Mescher et al., 1998). Brieﬂy, un-
wanted resonances in the PRESS spectrum are edited
using the J-coupling between the GABA resonances at
3.0 ppm and 1.9 ppm. By applying a frequency-
selective 180x pulse to the 1.9 ppm GABA resonance in
alternate acquisitions, a modulation is introduced to
the phase of the 3.0 ppm resonance. Uncoupled res-
onances, such as the creatine resonance at 3.0 ppm
that overlap the GABA peak at the same chemical
shift, are left unaﬀected by the frequency-selective
180x pulse, as are coupled resonances, such as glu-
tathione, that do not have a coupling partner within
the frequency range of the MEGA-PRESS pulse. Thus,
subtraction of the alternate scans reveals only the
components with a coupling partner within the band-
width of the frequency-selective 180x ; all other com-
ponents are cancelled by the subtraction. Speciﬁcally,
resonances from glutamate, glutamine, homo-
carnosine and the mobile brain macromolecules (MM)
are present in the edited sequence (see Figure 2 for
sample spectra).
(a)
(b)
Figure 1. T1-weighted image showing typical locations of (a)
the frontal voxel, (b) the occipital-parietal voxel.
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The parameters used during the acquisition of edi-
ted spectra were: TR=3 s, TE=68 ms, 128 averages,
1024 complex data-points. Total acquisition time for
each edited spectrum was y6.5 min. For both PRESS
and MEGA-PRESS acquisitions a 2 kHz spectral width
was used, centred on 2.5 ppm. Spatial localization
used Shinnar–Leroux-optimized 90x (pulse duration
2 ms, 5-lobe, 6085 ms-Hz time-bandwidth product)
and 180x (3 ms pulse duration, 5-lobe, 3850 ms-Hz
time-bandwidth product) pulses. The MEGA-PRESS
sequence incorporated a double-banded pulse with a
20 ms Gaussian envelope for spectral editing. The
GABA concentrations quoted here (total GABA) con-
tain GABA plus homocarnosine, which also has a
3 ppm resonance edited by this MEGA-PRESS se-
quence. Values in the literature show the homo-
carnosine contribution to be quite small, of the order of
0.46 mM (Petroﬀ et al., 2001).
Analysis was performed using the LC model (LCM;
Provencher, 1993). The linewidth, signal-to-noise
ratio and baseline of each spectrum were checked to
ensure the robustness of the data. Eddy current
correction was applied using an unsuppressed water
spectrum. The PRESS LCM basis functions (NAA,
NAAG, glutamate, glutamine, GABA, choline, cre-
atine, myo-inositol, taurine, alanine, lactate, aspartate,
glycerophosphocholine (GPC), phosphocholine (PCh),
glycine) were derived from phantom spectra at
TE=68 ms and simulated basis spectra of macro-
molecules and lipids. The analysis of edited spectra
used LCM basis functions (NAA, NAAG, glutamate,
glutamine, GABA) that were generated from phantom
measurements using the MEGA-PRESS sequence
with the appropriate acquisition parameters. To en-
sure consistency in the basis functions, all spectra
were analysed using the same spectral range
(0.2–4.0 ppm), and were unﬁltered. Spectra in which
GABA had a Cramer–Rao lower bound greater than
20% were rejected.
GABA detection methods that rely on J-diﬀerence
editing of the 3.0 ppm GABA resonance are likely to
include contamination from the nearby MM reson-
ance. To minimize this eﬀect, basis functions were
generated for the MM components visible in the edi-
ted spectra, which were then introduced into the LCM
analysis. The MM basis functions were derived from
in-vivo measurements in the occipital and frontal
voxels of a subset of subjects in the study using
the MEGA-PRESS editing sequence with an inversion-
recovery pre-pulse (14 ms hyperbolic inversion pulse,
TI=800 ms, TR=3 s with dummy scan preparation).
These spectra were analysed for all visible MM
peaks, resulting in a group-averaged ratio being de-
rived for the relative intensity of the MM peaks at 3.0
and 0.9 ppm. This group-averaged value was then in-
corporated, with a soft constraint, as a parameter in
the LCM ﬁt. Applying an inversion-recovery at the
beginning of the editing sequence can null the metab-
olite signal, revealing the contribution of the macro-
molecules to this edited spectrum due to their
substantially shorter T1 values. All metabolite con-
centrations were evaluated as ratios to creatine (Cr).
Glutamate and glutamine were measured together as
the ratio of Glx:Cr.
For subjects who were willing to remain in
the scanner (controls 6, recovered depressed 9),
T1-weighted structural images were acquired with
Glu +
Gln
(a)
(b)
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GABA +
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Figure 2. Typical MEGA PRESS spectra from control subjects
from (a) occipital voxel and (b) frontal [anterior cingulate
cortex (ACC)] voxel. Resonances visible in the edited spectra
are GABA+[GABA, MM (macromolecules) and homo-
carnosine], glutamate (Glu), glutamine (Gln) and NAA. Note
the broader linewidth and lower signal-to-noise ratio of ACC
spectrum due to local B0 ﬁeld inhomogeneity caused by the
frontal sinus.
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resolution 1r1r1 mm and segmented with FSL FAST
to calculate the grey matter fraction within the PRESS
volume (Zhang et al., 2001). In this subset of subjects
grey matter partial volumes did not diﬀer between
patients and controls.
Statistical methods
The GABA:Cr data were analysed with a two-way
repeated measures analysis of covariance (ANCOVA)
with ‘region’ (ACC vs. occipital cortex) as the main
within-subject factor while ‘group’ (recovered de-
pressed vs. control) was the main between-group fac-
tor (SPSS version 12; SPSS Inc., Chicago, IL, USA). The
Glx:Cr and NAA:Cr ratios were similarly analysed.
Unpaired t tests were used as post-hoc tests. Age was
a signiﬁcant correlate of the GABA:Cr and Glx:Cr ra-
tios and was added to the analyses as a covariate.
There were no main or interactive eﬀects of gender,
which was therefore omitted from the analyses.
Correlations were carried out using Pearson’s corre-
lation coeﬃcient.
Results
There was no signiﬁcant diﬀerence between the
groups in age (t=1.07, p=0.29), or gender (x2 p=0.3).
The ANCOVA of the GABA:Cr ratio showed a main
eﬀect of group (F=4.46, d.f.=1, 20, p=0.048). There
was no main eﬀect of brain region (F=1.01, d.f.=1, 20,
p=0.33) or grouprregion interaction (F=0.09, d.f.=1,
20, p=0.77). The reduction in GABA:Cr values in the
occipital cortex (10%) and ACC (11%) were very
similar (Figure 3). GABA:Cr ratios in the occipital
cortex correlated with those in the ACC (r=0.46,
p=0.027). Age correlated inversely with the GABA:Cr
ratio in both the occipital cortex (r=x0.55, p=0.007)
and ACC (r=x0.58, p=0.004).
The ANCOVA of the Glx:Cr ratio showed no sig-
niﬁcant main eﬀect of group or region; however, there
was a signiﬁcant interaction between group and re-
gion (F=6.95, d.f.=1, 19, p=0.016). In the occipital
cortex the Glx:Cr ratios in recovered patients were
signiﬁcantly higher than those of controls (mean¡
S.E.M.) (1.70¡0.07 vs. 1.44¡0.06, p=0.01). In the ACC,
however, Glx:Cr ratios were non-signiﬁcantly lower in
patients (1.44¡0.10 vs. 1.62¡0.06, p=0.16). Similarly
NAA:Cr ratios showed no signiﬁcant main eﬀect of
group or region but there was a signiﬁcant interaction
(F=6.88, d.f.=1, 19, p=0.017). In the ACC there was
no diﬀerence in NAA:Cr ratios between patients and
controls (1.39¡0.05 vs. 1.36¡0.03, p=0.53) while in
the occipital cortex there was a trend to reduction in
patients (1.54¡0.67 vs. 1.70¡0.04, p=0.068). Glx:Cr
ratios correlated negatively with age in the ACC
(x0.54, p=0.009) but not the occipital cortex (0.12,
p=0.57). There was no signiﬁcant correlation between
ACC and occipital values of Glx:Cr or NAA:Cr ratios.
In the ACC there was a signiﬁcant positive correlation
between GABA:Cr and Glx:Cr ratios (r=0.71,
p=0.001) but this was not apparent in the occipital
cortex (r=x0.37, p=0.075).
Discussion
We provide preliminary evidence that GABA:Cr ra-
tios are decreased in both occipital cortex and ACC in
recovered unmedicated subjects with a history of re-
current depression. The reductions we found (y10%)
were substantially less than those described by
Sanacora and colleagues who, using 1H-MRS, found
decreases in occipital GABA levels of y50%, in
acutely ill unmedicated patients with melancholic
depression (Sanacora et al., 1999). Depressed patients
not meeting criteria for melancholic depression had
smaller reductions of y20% in occipital GABA
(Sanacora et al., 2004). This raises the possibility that
clinical recovery from depression is associated with
some restoration of occipital GABA levels towards
normal, although a detectable deﬁciency apparently
remains.
Why GABA levels should be decreased in recovered
depressed subjects requires further investigation.
However, there is increasing evidence of neuropatho-
logical changes in cortical tissue in patients with re-
current aﬀective illness and reports of decreased glial
cell numbers in ACC might be relevant to our ﬁndings
(Harrison, 2002; Ongur et al., 1998). Glial cells, notably
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Figure 3.Mean (S.E.M.) GABA:Cr ratios in the anterior cingu-
late cortex (ACC) and occipital cortex (OC) in recovered de-
pressed subjects (&, n=12) and healthy controls (%, n=11).
Main eﬀect of group: F=4.46, d.f.=1, 20, p=0.048.
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astrocytes, are an important source of the GABA pre-
cursor, glutamine, to GABA nerve terminals (Shulman
et al., 2004) and it is therefore possible that impairment
of glial cell activity could lead to diminished GABA
synthesis and low tissue GABA levels (Sanacora et al.,
2004).
Another purpose of our study was to assess
whether changes in GABA levels in recovered de-
pressed subjects might also be present in frontal cor-
tical areas. Previous MRS work in acute depression
has focused on the occipital cortex because placing the
spectroscopic voxel in this brain region decreases in-
terference from static magnetic ﬁeld inhomogeneities,
thereby facilitating GABA measures. Our ﬁndings
show that recovered depressed patients appear to
show similar decreases in GABA levels in both the
ACC and occipital cortex. We also found a signiﬁcant
correlation between GABA levels in the two brain re-
gions.
Against this, Hasler and colleagues (2005) have re-
cently reported normal GABA levels in two regions of
pre-frontal cortex in a larger sample of subjects remit-
ted from major depression. The reason for this dis-
crepancy requires further study but it could reﬂect
diﬀerences in patient population. For example, some
of the patients in the latter study had experienced only
a single episode of depression, albeit in association
with a positive family history. In addition the location
of the frontal voxel in our study was centred on the
ACC rather than prefrontal cortex. However, because
of the size of the MRS voxel there would have been
substantial overlap between the tissue we sampled
and that reported by Hasler et al. (2005).
Interestingly in a subsequent MRS study in acutely
depressed patients, Hasler et al. (2007) found de-
creased levels of both GABA and Glx in the prefrontal
cortex. In both the present study and the larger sample
reported elsewhere (Bhagwagar et al., 2007) we found
increased levels of Glx in occipital cortex in recovered
depressed patients ; however, this change is appar-
ently not present in the ACC. Furthermore, Glx and
GABA levels showed a positive correlation in the ACC
but not occipital cortex. The former ﬁnding, which was
also reported by Hasler et al. (2007), suggests that
the coupling between GABA and Glx synthesis can
show striking regional variation. Despite this, our
ﬁndings suggest that GABA levels are decreased in
both ACC and occipital cortex. In depressed patients
GABA levels are also reportedly decreased in plasma
and cerebrospinal ﬂuid (see Brambilla et al., 2003).
This raises the possibility that low cortical levels of
GABA could be related to a more general defect in
GABA synthesis.
Methodological limitations of our study must also
be acknowledged. The number of patients and con-
trols studied was small, because it was diﬃcult for the
majority of subjects to remain in the scanner for suf-
ﬁcient time to allow acquisition of adequate spectra for
both brain regions. In addition, our GABA measures
have been referenced to creatine. While this is a com-
mon methodology in MRS studies (Coupland et al.,
2005), it leaves open the possibility that changes in
creatine concentrations between patient and control
groups could account for our ﬁndings. Finally, par-
ticularly in the ACC, there is a relatively low signal-
to-noise ratio of GABA spectra which is likely to aﬀect
the reliability of our data.
Further work is needed to establish whether de-
creased cortical GABA levels may be present in re-
covered patients with a history of recurrent depression
and if so what such a deﬁcit may mean in terms of
future risk of illness and response to maintenance
treatments.
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